2. Protein Tyrosine Kinase/RTK Metabolic Enzyme/Protease
  3. SHP2 Phosphatase
  4. Batoprotafib

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.

For research use only. We do not sell to patients.

CAS No. : 1801765-04-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Batoprotafib Related Antibodies

Top Publications Citing Use of Products

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.  [Abstract]

    Dose-response curves of inhibitor targeting SHP2 (Batoprotafib (0.1-500 nM)) (top left). Dose-response curves of HRS-4642 (bottom left), and growth inhibition matrices of indicated inhibitor combined with HRS-4642 (right) in FC1242.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Apr 6;14(1):1933.  [Abstract]

    Tumor proliferation in mice engrafted with chordoma cells (U-CH1 cell line-derived xenograft, CF539 PDX, or CF466 PDX) and treated with a SHP2 inhibitor (RMC-4550 or Batoprotafib (TNO155) (20 mg/kg; p.o.)). Points represent the mean tumor volume ± s.e.m. (n = 4 (control) or 5 (compound) tumors for each arm of the U-CH1/RMC-4550 study; n = 6 (compound) or 7 (control) tumors for each arm of the U-CH1/TNO155 study; n = 6 (control) or 7 (compound) tumors for each arm of the CF539 study; n = 7 tumors for each arm of the CF466 study).

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    Co-culture of three different groups of GC cells (oe-NC+DMSO, oe-NC+TNO155 (Batoprotafib) (1 μM; 24 h), oe-MEST+TNO155) with CD8+ T cells; qPCR detection of the expression of MHCI-related genes and SHP2 in GC cells. The results showed that TNO155 significantly promoted the expression of MCHI-related genes, and oe-MEST+TNO155 partially reversed the increase in MCHI-related gene expression.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    Co-culture of three different groups of GC cells (oe-NC+DMSO, oe-NC+TNO155 (Batoprotafib) (1 μM; 24 h), oe-MEST+TNO155) with CD8+ T cells; WB detection of the expression of MHCI-related genes and SHP2 in GC cells. The results showed that TNO155 significantly inhibited SHP2 expression, and oe-MEST+TNO155 restored SHP2 expression to the control group level.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    LDH assay of cytotoxicity of CD8+ T cells. The results showed that TNO155 (Batoprotafib) (1 μM; 24 h) significantly enhanced the killing of HGC-27 cells by CD8+ T cells, and further overexpression of MEST attenuated the increased cytotoxicity of CD8+ T cells.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    Flow cytometry analysis of cellular apoptosis. The results showed that compared to the control group, TNO155 (Batoprotafib) (1 μM; 24 h) significantly increased the apoptotic rate of HGC-27 cells, while further overexpression of MEST significantly reduced the apoptotic rate of HGC-27 cells.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    ELISA measurement of concentration of IFN-γ in cell culture supernatant. ELISA results indicated that compared to the control group, TNO155 (Batoprotafib) (1 μM; 24 h) significantly increased the levels of IFN-γ and TNF-α in the supernatant of HGC-27 cells, while after overexpression of MEST, the levels of IFN-γ and TNF-α in the supernatant were significantly reduced.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2024 Sep:174:106621.  [Abstract]

    Transwell measurement of the migration of GC cells after co-culturing with CD8+ T cells. Transwell assays revealed that the migration and invasion abilities of HGC-27 cells were significantly reduced upon the addition of TNO155 (Batoprotafib) (1 μM; 24 h), while in the oe-MEST+TNO155, the migration and invasion abilities of the tumor cells were restored to the control group level.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Res Commun. 2023 Dec 27;3(12):2608-2622.  [Abstract]

    Calculation of IC50 in neuroblastoma cells following treatment with Batoprotafib (TNO155) for 72 hours. **, P < 0.01; ***, P < 0.001.

    Batoprotafib purchased from MedChemExpress. Usage Cited in: Cancer Res Commun. 2023 Dec 27;3(12):2608-2622.  [Abstract]

    Western immunoblots of Kelly and SH-SY5Y cells treated with Batoprotafib (TNO155) (1 µmol/L), lorlatinib (1 µmol/L), or combination for 24 hours. Batoprotafib (TNO155) plus lorlatinib treatment showed marked inhibition of ALK and SHP2 activity, including inactivation of MAPK downstream signaling.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
    IC50 & Target

    IC50: 0.011 µM (SHP2)[1]
    Cellular Effect
    Cell Line Type Value Description References
    EMT6 IC50
    2.49 μM
    Compound: TNO155
    Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    		[PMID: 35447031]
    EMT6 IC50
    7.03 μM
    Compound: TNO155
    Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35447031]
    MDA-MB-231 IC50
    12.94 μM
    Compound: TNO155
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    		[PMID: 35447031]
    MDA-MB-231 IC50
    > 20 μM
    Compound: TNO155
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35447031]
    MDA-MB-468 IC50
    3.11 μM
    Compound: TNO155
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of abemaciclib by MTT assay
    		[PMID: 35447031]
    MDA-MB-468 IC50
    > 20 μM
    Compound: TNO155
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35447031]
    MV4-11 IC50
    39 nM
    Compound: 8; TNO155
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK-8 assay
    		[PMID: 39303516]
    In Vitro

    Batoprotafib shows an IC50 of 0.008 μM in KYSE520 pERK assay and shows an IC50 of 0.100 μM in KYSE520 5-day cell proliferation assay. The off-target IC50 values are 18 μM, 6.9 μM, and 11 μM for Cav1.2, VMAT, and SST3, respectively[1].
    Batoprotafib (0-1000 nM; 6 days) inhibits the viability of NCI-H3255, HCC827, and PC9 cells with IC50 values lower than 1.5 μM. Batoprotafib is efficacious in EGFR-mutant NSCLC cell lines[2].
    Batoprotafib is efficacious in acquired resistance models of EGFR inhibitors and demonstrates combination benefit with EGFR inhibitors[2].
    Batoprotafib enhances the efficacy of KRASG12C inhibitors against KRASG12C lung and colorectal cancers[2].
    Batoprotafib inhibits immune-suppressive macrophages and synergizes with PD1 blockade[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Batoprotafib Related Antibodies

    Cell Proliferation Assay[2]

    Cell Line: PC-9, PC-9 EGFRT790M/C797S, HCC827, HCC827-GR (gefinitib-resistant)
    Concentration: 0-1000 nM
    Incubation Time: 6 days
    Result: Inhibited cell viability with IC50s of 1.56, 1.38, 0.77 and 1.38 μM against PC-9 and PC-9 EGFRT790M/C797S, HCC827 and HCC827-GR cells, respectively.

    Western Blot Analysis[2]

    Cell Line: PC-14 (EGFRex19del)
    Concentration: 3 μM
    Incubation Time: 4h and 24 h
    Result: Effectively reduced p-ERK levels at 4 hours but suffered a rebound at 24 hours.
    In Vivo

    The oral bioavailability in mouse, rat and money are 78%, 86%, and 60%, respectively[1].
    Batoprotafib (20 mg/kg; p.o.; twice daily for 40 days) inhibits tumor growth and is more effective when combined with Dabrafenib.html" class="link-product" target="_blank">Dabrafenib (HY-14660) plus Trametinib.html" class="link-product" target="_blank">Trametinib (HY-10999) in nude mice bearing HT-29 xenografts[2].
    Batoprotafib (7.5 mg/kg; p.o.; b.i.d. or q.d. for 36 days) plus JDQ-443 (HY-139612) (100 mg/kg; p.o.; q.d.) improves the single-agent activity of JDQ443 in KRASG12C-mutated cell-derived (CDX) models in nude mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female athymic nude mice bearing HT-29 xenografts[2]
    Dosage: 20 mg/kg alone or 10 mg/kg in combination with Dabrafenib and Trametinib
    Administration: PO, twice daily for 40 days
    Result: Resulted in moderate tumor growth inhibition. Maintained tumor stasis for more than 40 days when combined with Dabrafenib plus Trametinib.
    Clinical Trial
    Molecular Weight

    421.95

    Formula

    C18H24ClN7OS
    CAS No.
    Appearance

    Solid

    Color

    Off-white to yellow

    SMILES

    N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 66.67 mg/mL (158.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3699 mL 11.8497 mL 23.6995 mL
    5 mM 0.4740 mL 2.3699 mL 4.7399 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.89%

    SDS (393 KB)

    COA (249 KB) HNMR (362 KB) RP-HPLC (254 KB) MS (69 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3699 mL 11.8497 mL 23.6995 mL 59.2487 mL
    5 mM 0.4740 mL 2.3699 mL 4.7399 mL 11.8497 mL
    10 mM 0.2370 mL 1.1850 mL 2.3699 mL 5.9249 mL
    15 mM 0.1580 mL 0.7900 mL 1.5800 mL 3.9499 mL
    20 mM 0.1185 mL 0.5925 mL 1.1850 mL 2.9624 mL
    25 mM 0.0948 mL 0.4740 mL 0.9480 mL 2.3699 mL
    30 mM 0.0790 mL 0.3950 mL 0.7900 mL 1.9750 mL
    40 mM 0.0592 mL 0.2962 mL 0.5925 mL 1.4812 mL
    50 mM 0.0474 mL 0.2370 mL 0.4740 mL 1.1850 mL
    60 mM 0.0395 mL 0.1975 mL 0.3950 mL 0.9875 mL
    80 mM 0.0296 mL 0.1481 mL 0.2962 mL 0.7406 mL
    100 mM 0.0237 mL 0.1185 mL 0.2370 mL 0.5925 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Batoprotafib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Batoprotafib1801765-04-7TNO155TNO 155TNO-155SHP2PhosphataseSrc homology phosphatase 2PTPN11RTK-dependentmalignancyAberrantactivationBCSallostericEGFR-mutantNSCLCHNSCCCRCInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Batoprotafib
    Cat. No.:
    HY-136173
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.